See more : Aurora Solar Technologies Inc. (ACU.V) Income Statement Analysis – Financial Results
Complete financial analysis of Vyant Bio, Inc. (VYNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vyant Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Monte Rosa Therapeutics, Inc. (GLUE) Income Statement Analysis – Financial Results
- Bioextrax AB (publ) (BIOEX.ST) Income Statement Analysis – Financial Results
- Major-Power Technology Co., Ltd. (6720.TWO) Income Statement Analysis – Financial Results
- Universal Security Instruments, Inc. (UUU) Income Statement Analysis – Financial Results
- Orion Nutraceuticals Inc. (ORI.CN) Income Statement Analysis – Financial Results
Vyant Bio, Inc. (VYNT)
About Vyant Bio, Inc.
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 666.00K | 1.15M | 867.00K | 7.31M | 27.47M | 29.12M | 27.05M | 18.04M | 10.20M | 6.61M | 4.30M | 3.02M | 2.52M | 1.67M |
| Cost of Revenue | 1.01M | 1.85M | 1.10M | 3.70M | 18.72M | 18.07M | 17.10M | 14.10M | 8.45M | 4.92M | 3.93M | 3.12M | 3.52M | 2.53M |
| Gross Profit | -342.00K | -699.00K | -234.00K | 3.60M | 8.75M | 11.05M | 9.95M | 3.94M | 1.75M | 1.69M | 372.57K | -98.00K | -994.61K | -865.93K |
| Gross Profit Ratio | -51.35% | -60.89% | -26.99% | 49.34% | 31.84% | 37.95% | 36.77% | 21.85% | 17.12% | 25.50% | 8.66% | -3.25% | -39.44% | -51.99% |
| Research & Development | 6.77M | 4.27M | 3.23M | 0.00 | 2.49M | 4.79M | 5.97M | 5.48M | 4.62M | 2.19M | 2.11M | 2.07M | 1.17M | 1.34M |
| General & Administrative | 0.00 | 0.00 | 6.60M | 5.17M | 19.18M | 19.89M | 16.03M | 14.57M | 12.37M | 6.12M | 4.50M | 4.44M | 3.45M | 1.84M |
| Selling & Marketing | 8.80M | 8.42M | 2.72M | 1.15M | 5.27M | 4.99M | 4.67M | 5.27M | 3.96M | 1.84M | 1.40M | 1.57M | 715.97K | 239.46K |
| SG&A | 8.80M | 8.42M | 2.72M | 6.32M | 24.45M | 24.88M | 20.70M | 19.84M | 16.33M | 7.96M | 5.90M | 6.01M | 4.16M | 2.08M |
| Other Expenses | 0.00 | 57.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.57M | 12.70M | 5.95M | 6.32M | 26.94M | 29.67M | 26.67M | 25.32M | 20.95M | 10.15M | 8.01M | 8.09M | 5.33M | 3.42M |
| Cost & Expenses | 16.58M | 14.54M | 7.05M | 10.02M | 45.66M | 47.74M | 43.77M | 39.42M | 29.41M | 15.07M | 11.94M | 11.20M | 8.84M | 5.95M |
| Interest Income | 0.00 | 0.00 | 0.00 | 108.00K | 21.00K | 63.00K | 23.00K | 49.00K | 73.80M | 29.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 93.00K | 0.00 | 535.00K | 1.44M | 2.12M | 2.13M | 454.00K | 344.00K | 472.82K | 2.39M | 4.70M | 1.31M | 792.42K | 2.09M |
| Depreciation & Amortization | 843.00K | 8.23M | 2.56M | 757.00K | 2.11M | 2.17M | 2.38M | 1.66M | 838.60K | 326.48K | 353.41K | 13.05K | 537.31K | 3.24K |
| EBITDA | -15.07M | -15.71M | -5.06M | -5.03M | -16.14M | -18.62M | -16.72M | -19.36M | -17.68M | -10.32M | -1.61M | -18.56M | -7.08M | -5.23M |
| EBITDA Ratio | -2,262.61% | -651.39% | -583.85% | -68.80% | -58.75% | -64.10% | -47.96% | -107.33% | -173.36% | -156.16% | -37.46% | -614.68% | -280.68% | -314.18% |
| Operating Income | -15.91M | -15.71M | -7.62M | -2.71M | -18.19M | -18.62M | -16.72M | -21.38M | -19.21M | -8.46M | -7.64M | -8.18M | -6.32M | -4.29M |
| Operating Income Ratio | -2,389.19% | -1,368.12% | -879.24% | -37.14% | -66.23% | -63.95% | -61.83% | -118.50% | -188.34% | -128.01% | -177.62% | -271.08% | -250.76% | -257.31% |
| Total Other Income/Expenses | 105.00K | -2.87M | -1.03M | -4.68M | -2.18M | -4.34M | 921.00K | 9.00K | 215.98K | -4.57M | 974.96K | -11.70M | -2.08M | -3.04M |
| Income Before Tax | -15.81M | -18.58M | -8.65M | -7.40M | -20.37M | -22.96M | -15.80M | -21.37M | -18.99M | -13.04M | -6.67M | -19.89M | -8.41M | -7.33M |
| Income Before Tax Ratio | -2,373.42% | -1,618.03% | -997.69% | -101.26% | -74.16% | -78.84% | -58.42% | -118.45% | -186.22% | -197.22% | -154.96% | -658.64% | -333.42% | -439.96% |
| Income Tax Expense | 6.88M | 27.52M | 546.00K | -512.00K | -59.00K | -2.08M | 1.38M | -1.18M | -2.35M | -663.90K | 5.68M | -10.39M | -1.29M | -950.49K |
| Net Income | -22.69M | -46.10M | -9.20M | -6.71M | -20.37M | -20.88M | -15.80M | -20.18M | -16.64M | -12.37M | -6.67M | -19.89M | -8.41M | -7.33M |
| Net Income Ratio | -3,406.91% | -4,015.24% | -1,060.67% | -91.83% | -74.16% | -71.70% | -58.42% | -111.88% | -163.18% | -187.18% | -154.96% | -658.64% | -333.42% | -439.96% |
| EPS | -3.87 | -10.19 | -18.50 | -17.40 | -111.98 | -151.58 | -149.45 | -294.00 | -264.20 | -397.81 | -278.28 | -381.45 | -350.99 | -305.94 |
| EPS Diluted | -3.87 | -10.19 | -18.50 | -17.40 | -111.98 | -151.58 | -149.45 | -293.97 | -263.85 | -396.90 | -277.98 | -381.45 | -350.61 | -305.61 |
| Weighted Avg Shares Out | 5.87M | 4.53M | 497.20K | 385.60K | 181.94K | 137.75K | 105.74K | 68.65K | 62.99K | 31.10K | 23.95K | 52.14K | 23.95K | 23.95K |
| Weighted Avg Shares Out (Dil) | 5.87M | 4.53M | 497.20K | 385.60K | 181.94K | 137.75K | 105.74K | 68.66K | 63.08K | 31.17K | 23.98K | 52.14K | 23.98K | 23.98K |
Why Is Vyant Bio (VYNT) Stock Down 35% Today?
Vyant Bio (NASDAQ: VYNT ) stock is taking a beating on Tuesday after the biotechnology company announced plans to delist its shares. According to a press release, the company's Board of Directors determined that a voluntary delisting of shares was...
Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives
Vyant Bio (NASDAQ:VYNT) has told investors that the company's president and CEO John Roberts and chief scientific officer Dr Robert Fremeau have agreed in principle to step down from their respective positions, effective today, February 3, to preserve cash for...
Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value
Vyant Bio (NASDAQ:VYNT) Inc has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value. The biotechnology company also said it is participating in BIO's One-on-One Partnering event in San...
Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript
Vyant Bio, Inc. (NASDAQ:VYNT ) Q3 2022 Earnings Conference Call November 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Dr. Robert Fremeau - Chief Scientific Officer Conference Call Participants...
Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show
Vyant Bio (NASDAQ:VYNT) Inc has reported its third-quarter financial results and announced it expects to be able to fund operations through to at least the end of 2023. The company had $9.4 million of cash and equivalents as of September...
Vyant Bio showcases 'promise and potential' of its drug discovery platform at Boston medical conference
Vyant Bio (NASDAQ:VYNT) Inc senior scientist Matthew Green delivered poster presentations this week at the Loulou Foundation's CDKL5 forum held in Boston. CDKL5 (cyclin-dependent kinase-like 5) deficiency disorder (CDD) is a rare neurodevelopmental condition caused by pathogenic mutations in the...
Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million
Vyant Bio (NASDAQ:VYNT) Inc said it has closed a definitive agreement with Reaction Biology Corporation in the sale of its subsidiary vivoPharm LLC, allowing Reaction to expand its suite of drug discovery services. According to Vyant Bio (NASDAQ:VYNT), Reaction will...
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
- To Discuss its Novel Drug Discovery Platform that i s A ccelerat ing the P rocess of F inding C ures for N eurogenerative D iseases
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug...
Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year
Vyant Bio (NASDAQ:VYNT) Inc revealed that it is advancing its repurposed drug candidate, VYNT-0126 to treat Rett Syndrome, into clinical trials early next year based on pre-clinical efficacy data and following encouragement and guidance from the International Rett Syndrome Foundation (IRSF),...
Source: https://incomestatements.info
Category: Stock Reports